View in EDS

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.

Saved in:
Bibliographic Details
Title: Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.
Authors: Krämer A; Clinical Cooperation Unit Molecular Hematology-Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. Electronic address: a.kraemer@dkfz-heidelberg.de., Bochtler T; Clinical Cooperation Unit Molecular Hematology-Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Pauli C; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland; Medical Faculty, University of Zurich, Zurich, Switzerland., Shiu KK; UCLH Gastrointestinal Oncology Service, Cancer of Unknown Primary Service, University College London, Cancer Institute, London, UK., Cook N; The Christie NHS Foundation Trust and Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK., de Menezes JJ; Clinical Oncology, Centro Integrado de Pesquisa em Oncologia, Porto Alegre, Brazil., Pazo-Cid RA; Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain., Losa F; Medical Oncology Department, Hospital de Sant Joan Despí Moisès Broggi, ICO Hospitalet, Barcelona, Spain., Robbrecht DG; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands., Tomášek J; Masaryk Memorial Cancer Institute, Brno, Czech Republic., Arslan C; Izmir University of Economics Medical Point Hospital, Izmir, Türkiye., Özgüroğlu M; Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Internal Medicine, Division of Oncology, Istanbul, Türkiye., Stahl M; Evang Kliniken Essen-Mitte, Essen, Germany., Bigot F; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France., Kim SY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Naito Y; Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan., Italiano A; Institut Bergonie, Early Phase Trials and Sarcoma Units, Bordeaux, France., Chalabi N; Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland., Durán-Pacheco G; Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland., Michaud C; Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland., Scarato J; Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland., Thomas M; Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland., Ross JS; Pathology Group, Foundation Medicine, Cambridge, MA, USA; Upstate Medical University Departments of Pathology, Urology and Medicine (Oncology), Syracuse, NY, USA., Moch H; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland; Medical Faculty, University of Zurich, Zurich, Switzerland., Mileshkin L; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Source: Lancet (London, England) [Lancet] 2024 Aug 10; Vol. 404 (10452), pp. 527-539. Date of Electronic Publication: 2024 Jul 31.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Comparative Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39096924
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Krämer+A%22">Krämer A</searchLink>; Clinical Cooperation Unit Molecular Hematology-Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. Electronic address: a.kraemer@dkfz-heidelberg.de.<br /><searchLink fieldCode="AU" term="%22Bochtler+T%22">Bochtler T</searchLink>; Clinical Cooperation Unit Molecular Hematology-Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Pauli+C%22">Pauli C</searchLink>; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland; Medical Faculty, University of Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Shiu+KK%22">Shiu KK</searchLink>; UCLH Gastrointestinal Oncology Service, Cancer of Unknown Primary Service, University College London, Cancer Institute, London, UK.<br /><searchLink fieldCode="AU" term="%22Cook+N%22">Cook N</searchLink>; The Christie NHS Foundation Trust and Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22de+Menezes+JJ%22">de Menezes JJ</searchLink>; Clinical Oncology, Centro Integrado de Pesquisa em Oncologia, Porto Alegre, Brazil.<br /><searchLink fieldCode="AU" term="%22Pazo-Cid+RA%22">Pazo-Cid RA</searchLink>; Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain.<br /><searchLink fieldCode="AU" term="%22Losa+F%22">Losa F</searchLink>; Medical Oncology Department, Hospital de Sant Joan Despí Moisès Broggi, ICO Hospitalet, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Robbrecht+DG%22">Robbrecht DG</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Tomášek+J%22">Tomášek J</searchLink>; Masaryk Memorial Cancer Institute, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Arslan+C%22">Arslan C</searchLink>; Izmir University of Economics Medical Point Hospital, Izmir, Türkiye.<br /><searchLink fieldCode="AU" term="%22Özgüroğlu+M%22">Özgüroğlu M</searchLink>; Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Internal Medicine, Division of Oncology, Istanbul, Türkiye.<br /><searchLink fieldCode="AU" term="%22Stahl+M%22">Stahl M</searchLink>; Evang Kliniken Essen-Mitte, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Bigot+F%22">Bigot F</searchLink>; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.<br /><searchLink fieldCode="AU" term="%22Kim+SY%22">Kim SY</searchLink>; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Naito+Y%22">Naito Y</searchLink>; Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Italiano+A%22">Italiano A</searchLink>; Institut Bergonie, Early Phase Trials and Sarcoma Units, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Chalabi+N%22">Chalabi N</searchLink>; Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Durán-Pacheco+G%22">Durán-Pacheco G</searchLink>; Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Michaud+C%22">Michaud C</searchLink>; Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Scarato+J%22">Scarato J</searchLink>; Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Thomas+M%22">Thomas M</searchLink>; Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Ross+JS%22">Ross JS</searchLink>; Pathology Group, Foundation Medicine, Cambridge, MA, USA; Upstate Medical University Departments of Pathology, Urology and Medicine (Oncology), Syracuse, NY, USA.<br /><searchLink fieldCode="AU" term="%22Moch+H%22">Moch H</searchLink>; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland; Medical Faculty, University of Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Mileshkin+L%22">Mileshkin L</searchLink>; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2024 Aug 10; Vol. 404 (10452), pp. 527-539. <i>Date of Electronic Publication: </i>2024 Jul 31.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Comparative Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39096924
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(24)00814-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 527
    Titles:
      – TitleFull: Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Krämer A
      – PersonEntity:
          Name:
            NameFull: Bochtler T
      – PersonEntity:
          Name:
            NameFull: Pauli C
      – PersonEntity:
          Name:
            NameFull: Shiu KK
      – PersonEntity:
          Name:
            NameFull: Cook N
      – PersonEntity:
          Name:
            NameFull: de Menezes JJ
      – PersonEntity:
          Name:
            NameFull: Pazo-Cid RA
      – PersonEntity:
          Name:
            NameFull: Losa F
      – PersonEntity:
          Name:
            NameFull: Robbrecht DG
      – PersonEntity:
          Name:
            NameFull: Tomášek J
      – PersonEntity:
          Name:
            NameFull: Arslan C
      – PersonEntity:
          Name:
            NameFull: Özgüroğlu M
      – PersonEntity:
          Name:
            NameFull: Stahl M
      – PersonEntity:
          Name:
            NameFull: Bigot F
      – PersonEntity:
          Name:
            NameFull: Kim SY
      – PersonEntity:
          Name:
            NameFull: Naito Y
      – PersonEntity:
          Name:
            NameFull: Italiano A
      – PersonEntity:
          Name:
            NameFull: Chalabi N
      – PersonEntity:
          Name:
            NameFull: Durán-Pacheco G
      – PersonEntity:
          Name:
            NameFull: Michaud C
      – PersonEntity:
          Name:
            NameFull: Scarato J
      – PersonEntity:
          Name:
            NameFull: Thomas M
      – PersonEntity:
          Name:
            NameFull: Ross JS
      – PersonEntity:
          Name:
            NameFull: Moch H
      – PersonEntity:
          Name:
            NameFull: Mileshkin L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 08
              Text: 2024 Aug 10
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 404
            – Type: issue
              Value: 10452
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1